Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19‐9 levels
- 13 March 2023
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 30 (7) , 924-934
Abstract
Background/Purpose: The efficacy of neoadjuvant treatment (NAT) for resectable pancreatic cancer remains debatable, particularly in patients with portal vein (PV)/superior mesenteric vein (SMV) contact and elevated serum carbohydrate antigen (CA) 19‐9. This study investigated the clinical significance of PV/SMV contact and CA19‐9 levels, and the role of NAT in resectable pancreatic cancer.Methods: A total of 775 patients who underwent surgery for resectable pancreatic cancer between 2007 and 2018 were included. Propensity score‐matched (PSM) analysis (1:3) was performed based on tumor size, lymph node enlargement, and PV/SMV contact. Subgroup analyses were performed according to PV/SMV contact and CA19‐9 level.Results: Among the patients, 52 underwent NAT and 723 underwent upfront surgery. After PSM, NAT group showed better survival than upfront surgery group (median 30.0 vs 22.0 months, P = .047). In patients with PV/SMV contact, NAT tended to have better survival (30.0 vs 22.0 months, P = .069). CA19‐9 >150 U/mL was a poor prognostic factor, with NAT showing a significant survival difference compared with upfront surgery (34.0 vs 18.0 months, P = .004).Conclusions: Neoadjuvant treatment showed better survival than upfront surgery in resectable pancreatic cancer. In patients with PV/SMV contact or CA19‐9 >150 U/mL, NAT showed a survival difference compared to upfront surgery; therefore, NAT could be considered in these patients.Keywords
Funding Information
- Ministry of Science and ICT, South Korea (NRF‐2017M3C9A5031591)
- National Research Foundation of Korea (2022R1A2C2011122)
This publication has 27 references indexed in Scilit:
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017Pancreatology, 2018
- Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trialBMC Surgery, 2017
- Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancerAnnals of Surgical Treatment and Research, 2017
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014
- Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic CancerJournal of Gastrointestinal Surgery, 2013
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 2012
- Prognostic Impact of Postoperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic CancerAnnals of Surgical Oncology, 2011
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)BMC Cancer, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008